Inhibitor of lipases. The ingestion of orlistat inhibits gastric and pancreatic lipases. As a result of impaired cleavage of edible fats and decreases their absorption from the digestive tract. Orlistat the systematic use of this effect leads to the reduction of body weight in patients with obesity. Orlistat is practically not absorbed from the digestive tract and therefore virtually does not exert resorptive action.According to the Physician Desk Reference (2009), orlistat is indicated for the treatment of obesity, including reducing and maintaining body weight, in combination with a low-calorie diet. Orlistat is also indicated to reduce the risk of repeated increase of body weight after its initial decrease. Orlistat is shown to patients with obesity when body mass index ≥30 kg/m2 or ≥27 kg/m2 in the presence of other risk factors (diabetes, arterial hypertension, dyslipidemia).Orlistat
No products were found matching your selection.